{
  "id": 15710520,
  "title": "Health authorities dismiss reports of insulin shortage, cite unavailability of one brand",
  "url": "https://urgent.news/2026/10/20/health-authorities-dismiss-reports-of-insulin-shortage-cite",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-20T06:24:29.000Z",
  "source": {
    "name": "Dawn - Pakistan",
    "slug": "dawn-pakistan",
    "url": "https://www.dawn.com/news/2038490/health-authorities-dismiss-reports-of-insulin-shortage-cite-unavailability-of-one-brand"
  },
  "original_language": "en",
  "account": "Islamabad - Health authorities have dismissed claims of a nationwide insulin shortage, stating that only one brand is currently unavailable due to international supply issues. This clarification followed social media reports of an alleged shortage across Pakistan. The health ministry and the Drug Regulatory Authority of Pakistan (Drap) stated that alternatives for the unavailable brand remain accessible in the market. According to the ministry spokesperson, insulin glulisine (Apidra, Sanofi) is currently unavailable, but rapid-acting analogues such as insulin aspart (NovoRapid, Novo Nordisk) and insulin lispro (Humalog, Eli Lilly) are widely available. The spokesperson emphasized that all other primary insulin classes are fully accessible nationwide. Patients prescribed Apidra are advised to consult their healthcare provider before altering their regimen, as any switch to an alternative formulation requires careful dose adjustment and monitoring. In August 2025, the Pakistan Medical Association had expressed alarm over a severe shortage of essential medicines, warning that the crisis threatened the lives of millions. The association noted that at least 80 important medicines were unavailable, with 25 lacking substitutes, including drugs for diabetes, cancer, Alzheimer’s, Parkinson’s, heart disease, and psychiatric disorders.",
  "summary": "ISLAMABAD: Authorities on Tuesday denied reports of a widespread insulin shortage in the country, saying that only one brand was unavailable due to international supply constraints. The clarification came after reports of a shortage across Pakistan emerged on social media. The health ministry and the Drug Regulatory Authority of Pakistan (Drap) maintained that alternatives for the unavailable…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}